In 2000, the European Union (EU) legislated to encourage the pharmaceutical industry to develop ‘orphan’ drugs (i.e. drugs for rare diseases).1 Incentives include up to 10-year market exclusivity, licensing fee reductions, and initiatives supporting research and development.1 Without incentives, such drugs would be unlikely to attract industry investment. However, sometimes there has been a high resulting price …